Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Centrum Capital Limited - Shareholders meeting

2018-05-07 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
501150 CENTRUM

0
Centrum Capital Limited - Shareholders meeting

2018-05-05 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
501150 CENTRUM

59
Airbus, Lockheed Rush to Tap India's $620 Billion Defense Market - Bloomberg

2018-04-11 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
501150 LMT DUAVF AM CENTRUM AIR BOE SAABF BA

0
Centrum Capital Limited - Shareholders meeting

2018-04-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
501150 CENTRUM

0
Centrum Capital Limited - Updates

2018-04-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
501150 CENTRUM

0
Centrum Capital on radar as it sells forex arm

2018-04-03 thehindubusinessline
Shares of Centrum Capital will remain in investors’ focus, as the Centrum group has decided to exit its forex business under the brand name Centrum Direct, by selling it to Atlanta-based Ebix Inc for about ₹1,200 crore. As part of the deal, the entire Centrum Direct team and assets will be transferred to Ebix and will become part of EbixCash, an end-to-end financial exchange.
501150 CENTRUM

1
Ebix Takes Leadership Position in India’s Foreign Exchange and Outward Remittance Markets with Agreement to Acquire CentrumDirect Limited

2018-04-03 globenewswire
JOHNS CREEK, Ga., April 03, 2018 (GLOBE NEWSWIRE) -- Ebix, Inc. (NASDAQ:EBIX), a leading international supplier of On-Demand software and E-commerce services to the insurance, financial, e-governance and healthcare industries, today announced that it has entered into an agreement to acquire India based CentrumDirect Limited (CDL), the undisputed Leader in India’s Foreign Exchange and outward remittance markets for approximately $175 million.
501150 CENTRUM EBIX

1
UPDATE 1-India's Centrum Group to sell money exchange business to US-based Ebix

2018-04-03 reuters
April 3 (Reuters) - India’s Centrum Capital Ltd said on Tuesday its parent Centrum Group had agreed to sell its money exchange business, Centrum Direct, to U.S.-based Ebix Inc for about 12 billion rupees ($184.6 million).
501150 CENTRUM EBIX

0
Centrum group to sell money exchange business to US-based Ebix

2018-04-03 livemint
Bengaluru: India’s Centrum Capital Ltd said on Tuesday the parent Centrum group agreed to sell its money exchange business to US-based Ebix Inc for about Rs1,200 crore ($184.60 million).
501150 CENTRUM

1
India's Centrum Group to sell money exchange business to U.S.-based Ebix

2018-04-03 reuters
April 3 (Reuters) - India’s Centrum Capital Ltd said on Tuesday the parent Centrum group agreed to sell its money exchange business to U.S.-based Ebix Inc for about 12 billion rupees ($184.60 million).
501150 CENTRUM EBIX

0
Centrum Group looks to enter insurance, stressed assets business

2018-03-13 livemint
Mumbai: Centrum Group is exploring entry into new lines of business such as stressed assets and insurance, even as the group is looking to boost its existing lending businesses with a fund-raise of around Rs500 crore.
501150 513250 CENTRUM JYOTISTRUC

Related Articles

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

NVRO: Nevro Corp Analysis and Research Report

2018-07-06 - Asif

Overview Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from chronic pain. Nevro has developed and commercialized the Senza® spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company's proprietary paresthesia-free HF10TM therapy, delivered by its Senza system, was demonstrated in its SENZA-RCT study to be superior to traditional SCS therapy with it being nearly twice as successful in treating back pain and 1.5 times as successful in treating leg pain when compared to traditional SCS therapy. Comparatively, traditional SCS therapy has limited efficacy in treating back pain and is used primarily for treating leg pain, limiting its market adoption. The company's SENZA-RCT study, along with its European studies, represents what the company believe is the most robust body of clinical evidence for any SCS therapy. The compa...